UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
US$ ११८.०९
arrow_downward
-२.४०%(-२.९०) 1D
US$ ११८.४०
arrow_upward
+०.२६% (+०.३१)todayPre-market
Closed: सेप्टेम्बर १६, १६:००:०० GMT-४ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
US$ १२०.१०
High
US$ १२०.८७
Low
US$ ११७.८४
Mkt. cap
४०.१३ अरब
Avg. vol.
४७.४६ हजार
Volume
१.२० हजार
52-wk high
US$ १६८.७६
52-wk low
US$ ११४.५२
Beta
०.५७
Shares outstanding
३८.९० करोड
No. of employees
९ हजार
Open
US$ १२०.१०
High
US$ १२०.८७
Low
US$ ११७.८४
Mkt. cap
४०.१३ अरब
Avg. vol.
४७.४६ हजार
Volume
१.२० हजार
52-wk high
US$ १६८.७६
52-wk low
US$ ११४.५२
Beta
०.५७
Shares outstanding
३८.९० करोड
No. of employees
९ हजार
News stories
From web sources and news partners
ad-hoc-news.de
·
१ दिन पहिले
UCB stock gains on Alphavalue price target increase
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR